<DOC>
	<DOCNO>NCT01711216</DOCNO>
	<brief_summary>Dydrogesterone approve 100 country include Russia , Ukraine , Kazakhstan Uzbekistan widely use treatment progesterone deficiencies management dysmenorrhea , endometriosis , secondary amenorrhea , irregular cycle , dysfunctional uterine bleeding , pre-menstrual syndrome , threaten habitual miscarriage , infertility due luteal insufficiency , well part hormone replacement therapy . There limited data regard dydrogesterone 's role achieve cycle regularization post-marketing setting . There need ass persistence dydrogesterone therapy post-marketing set cessation treatment whether persistence , , related duration dydrogesterone therapy . Hence , observational program , goal observe possible implication treatment term treatment length response pattern .</brief_summary>
	<brief_title>Treatment Regimen Menstrual Cycle Regularization Persistence Routine Clinical Practice Russia , Ukraine , Kazakhstan Uzbekistan</brief_title>
	<detailed_description>The program design prospective , multicentre , observational , non-interventional , non-randomized , non-controlled , single arm , post-marketing program . Being observational program , assignment patient dydrogesterone therapy decide intention include patient program , guide per standard clinical practice treat physician . Hence prescribe dydrogesterone clearly separate decision include patient program . All dydrogesterone prescription make accordance locally approve package insert dydrogesterone .</detailed_description>
	<mesh_term>Dydrogesterone</mesh_term>
	<criteria>Inclusion Criteria Women age 1840 year Irregular menstrual cycle due progesterone deficiency least 3 month Dydrogesterone prescribe accordance locally approve package insert Signed write authorization provide data program Exclusion Criteria Known hypersensitivity active ingredient excipients Known suspected progesteronedependent neoplasms Vaginal bleeding unknown etiology Administration oral contraceptive Any condition precludes use dydrogesterone particular patient , accordance contraindication , precaution special warning list locally approve package insert ( example , patient rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Dydrogesterone</keyword>
	<keyword>Irregular Menstrual Cycle</keyword>
	<keyword>Progestins</keyword>
</DOC>